Ligand Pharma (LGND) Introduces 2025 Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/19/2026
- Tech selloff weighs down Wall Street as bond yields climb
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Tech selloff weighs down Wall Street as bond yields climb
- Francisco Partners to acquire Weave Communications for $650M
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Goldman Sachs to acquire real estate company LCN for up to $410M
- BofA raises hyperscaler AI capex outlook to $3.6tn through 2028
Ligand Hosts 2024 Investor and Analyst Day and Introduces 2025 Guidance
December 10, 2024 9:00 AM ESTIntroduces 2025 full year revenue guidance of $180 million to $200 million, a 17% increase in revenue growth over 2024, and core adjusted earnings per diluted share of $6.00 to $6.25 Twelve commercial-stage programs and late-stage pipeline are expected to drive strong revenue growth over the next five years Long-term royalty receipts expected to deliver at least a 22% compound annual growth rate
JUPITER, Fla.--(BUSINESS WIRE)-- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) will host its Investor and Analyst Day in Boston today. The event will feature presentations from... More
